On Friday close, the FTSE 100 concluded at 8,004, reflecting a weekly gain of 122 points or 1.55%. This achievement means that the company finished the week above the significant
On Friday close, the FTSE 100 concluded at 8,004, reflecting a weekly gain of 122 points or 1.55%. This achievement means that the company finished the week above the significant
Leeds, UK, 15 February 2023 – 4D pharma plc (the “Company”) (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class
4D pharma Announces Updated Results from the Renal Cell Carcinoma Cohort of the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab)
Leeds, UK – December 30, 2022 – 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Overall, it was a decent week for London’s junior markets, with AIM100 up 0.39% to 4,034 though it lagged against the Footsie, which rose more than 0.8%.
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
During the week Zak was fortunate enough to bump into a stockbroker who, with more than 30 years in the saddle, can be regarded as one of the leaders in
4D pharma Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)
Looking at the daily chart of the FTSE Small Cap index the good news is that we appear to have hit the floor of the falling trend channel from the
Leeds, UK, September 28, 2022 , – 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from
Ofgem increased the energy price cap Friday to £3,549 per household. One pressure group stated it will sue Ofgem for its 80% price-cap increase, which it claims will ‘devastate families’ in